Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 4.5% - Should You Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) traded up 4.5% during trading on Tuesday . The company traded as high as $27.67 and last traded at $27.67. 36,133 shares changed hands during trading, a decline of 81% from the average session volume of 192,802 shares. The stock had previously closed at $26.48.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on DNTH shares. Baird R W upgraded Dianthus Therapeutics to a "strong-buy" rating in a report on Friday, July 26th. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They issued an "outperform" rating and a $58.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Lifesci Capital raised shares of Dianthus Therapeutics to a "strong-buy" rating in a research note on Tuesday, June 11th. Finally, Wedbush reduced their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a research report on Friday, August 9th. Nine research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $45.13.

Dianthus Therapeutics Price Performance

The firm has a fifty day simple moving average of $27.82 and a 200 day simple moving average of $26.21. The company has a market cap of $821.48 million, a price-to-earnings ratio of -4.86 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The firm had revenue of $1.86 million during the quarter, compared to the consensus estimate of $0.63 million. Analysts expect that Dianthus Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently modified their holdings of DNTH. Octagon Capital Advisors LP raised its position in shares of Dianthus Therapeutics by 15.4% during the fourth quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company's stock valued at $5,762,000 after buying an additional 74,000 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new stake in shares of Dianthus Therapeutics in the 1st quarter worth approximately $630,000. Vanguard Group Inc. grew its holdings in shares of Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company's stock worth $16,135,000 after purchasing an additional 384,182 shares in the last quarter. StemPoint Capital LP acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter worth approximately $1,304,000. Finally, Bain Capital Life Sciences Investors LLC acquired a new position in shares of Dianthus Therapeutics in the first quarter valued at $89,761,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.